WARREN, N.J. – PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company focused on the discovery and development of orally administered drugs, announced today the granting of inducement awards to newly hired employees. These awards, approved on September 28, 2025, are intended to incentivize and attract top talent to the company, aligning their interests with the long-term success of PTC Therapeutics.

The inducement grants consist of non-statutory stock options and restricted stock. Specifically, the company authorized stock options to purchase a total of 19,475 shares of PTC Therapeutics' common stock. Additionally, 39,060 shares of restricted stock were granted to the new employees.

These grants were made as an inducement material to the individuals accepting employment with PTC Therapeutics, and were approved in accordance with Nasdaq Listing Rule 5635(c)(4). This particular rule allows companies to grant equity-based compensation to new employees without requiring shareholder approval, provided the grants are approved by an independent compensation committee or a majority of the company’s independent directors. This exception is designed to facilitate the hiring process and ensure companies can quickly and efficiently attract qualified personnel.

The granting of these inducement awards reflects PTC Therapeutics' commitment to building a strong and motivated workforce. By offering equity in the company, PTC aims to foster a sense of ownership and encourage employees to contribute to the company's continued growth and success in developing innovative therapies for patients with unmet medical needs. The stock options and restricted stock provide employees with a stake in the company's future, aligning their financial interests with those of PTC Therapeutics and its shareholders. Further details regarding the terms and conditions of these grants can be found in the company’s filings with the Securities and Exchange Commission (SEC).